Biospectal SA, a Lausanne, Switzerland-based remote patient monitoring and biosensing software company, announces the closing of a $4.3 million round of seed funding led by digital health investor SeedLink, with additional funding from LabCorp, Athensmed, Swiss-based Privilege Ventures, and other European and U.S. investors.

Biospectal will leverage the new funds to scale its OptiBP smartphone blood pressure monitoring application and data platform technology worldwide. Biospectal OptiBP for Android launched in public beta in January 2021. Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021.

“Biospectal’s technology has the ability to transform the global network of smartphones into a connected, clinical-grade blood pressure monitoring platform that shifts clinical capabilities out of the traditional institutional settings,” says Biospectal CEO and Co-founder Eliott Jones. 

“The funding we’ve received will accelerate Biospectal’s growth trajectory along with the appointments of Silicon Valley-based, interventional cardiologist and influential serial healthcare innovator Fred St. Goar, MD; Tim Juergens, general manager and co-founder of SeedLink; William Hanlon from LabCorp; and Kustaa Piha, successful health tech entrepreneur and investor from Athensmed to the Biospectal Board of Directors,” adds Reinhard Stary, executive chairman of the board.

How Biospectal OptiBP Works

Biospectal’s OptiBP medical-grade app uses a smartphone camera’s optical lens to easily measure and record a user’s blood pressure flow via their fingertip. Biospectal’s proprietary algorithms and optical signal capture methods transform the captured data into blood pressure values in approximately 20 seconds — half the time of a typical blood pressure cuff. 

With Biospectal OptiBP, anyone in the world with a smartphone can turn their device into a connected, smart, clinical-grade monitor in the time it takes to download and install an app. OptiBP’s data also connects seamlessly with clinicians to support treatment regimens that help improve health and quality of life. Biospectal’s patented OptiBP technology replaces the antiquated, impractical traditional blood pressure cuff and brings medical-grade blood pressure measurement to the ‘point of patient’ without the need for yet another wearable device or additional bulky hardware that can break or needs to be replaced.

“I’m honored to join Biospectal’s board of directors,” says St. Goar. “Addressing the global hypertension crisis through more frequent and meaningful monitoring has become more critical and important than ever — a need that the onset of COVID-19 and demand for telehealth solutions has only amplified. People need an easy-to-use, digital means to accurately measure, monitor, track, and share their blood pressure data with their doctors. Biospectal is the first company I’ve encountered in the remote patient monitoring sector to bring an accessible, secure, and customer-centric blood pressure monitoring technology to market at global scale. Biospectal OptiBP is a game changer that promises to have a huge impact on improved access to and treatment of hypertension management.”